中国实用医刊
中國實用醫刊
중국실용의간
CENTRAL PLAINS MEDICAL JOURNAL
2014年
3期
14-16
,共3页
甘精胰岛素%二甲双胍%阿卡波糖%2型糖尿病
甘精胰島素%二甲雙胍%阿卡波糖%2型糖尿病
감정이도소%이갑쌍고%아잡파당%2형당뇨병
Glargine insulin%Metformin%Acarbose%Type 2 diabetes patients
目的 比较甘精胰岛素联合二甲双胍或/(和)阿卡波糖治疗新诊断2型糖尿病的临床疗效及安全性.方法 选取84例新诊断2型糖尿病患者,病史:有体质量下降,体质量指数(BMI) 23 ～ 28 kg/m2,先服用二甲双胍至少4周,血糖控制不佳,空腹血糖≥10 mmol/L,餐后2h血糖(2 h BG)≥14 mmol/L的患者随机分为三组.A组:二甲双胍加甘精胰岛素;B组:阿卡波糖加甘精胰岛素;C组:二甲双胍与阿卡波糖加甘精胰岛素,随访12周.结果 ①三组治疗后空腹血糖、2hBG、糖化血红蛋白(HbA1 c)均低于治疗前,A、B两组HbA1c部分达标,C组HbA1c全部达标(P＜0.05).②C组疗效优于A、B组,达标时间最短,日胰岛素用量最少.③A、B组BMI无增加,C组BMI有所下降(P＞0.05).④三组低血糖发生率均＜1 1％,无严重低血糖事件发生,差异无统计学意义(P＞0.05).结论 甘精胰岛素联合二甲双胍或/(和)阿卡波糖均能较好地控制血糖,对体质量影响小,低血糖发生率低,三药联合疗效优于二药联合,总体安全、有效、方便,是新诊断2型糖尿病理想的治疗方案.
目的 比較甘精胰島素聯閤二甲雙胍或/(和)阿卡波糖治療新診斷2型糖尿病的臨床療效及安全性.方法 選取84例新診斷2型糖尿病患者,病史:有體質量下降,體質量指數(BMI) 23 ～ 28 kg/m2,先服用二甲雙胍至少4週,血糖控製不佳,空腹血糖≥10 mmol/L,餐後2h血糖(2 h BG)≥14 mmol/L的患者隨機分為三組.A組:二甲雙胍加甘精胰島素;B組:阿卡波糖加甘精胰島素;C組:二甲雙胍與阿卡波糖加甘精胰島素,隨訪12週.結果 ①三組治療後空腹血糖、2hBG、糖化血紅蛋白(HbA1 c)均低于治療前,A、B兩組HbA1c部分達標,C組HbA1c全部達標(P＜0.05).②C組療效優于A、B組,達標時間最短,日胰島素用量最少.③A、B組BMI無增加,C組BMI有所下降(P＞0.05).④三組低血糖髮生率均＜1 1％,無嚴重低血糖事件髮生,差異無統計學意義(P＞0.05).結論 甘精胰島素聯閤二甲雙胍或/(和)阿卡波糖均能較好地控製血糖,對體質量影響小,低血糖髮生率低,三藥聯閤療效優于二藥聯閤,總體安全、有效、方便,是新診斷2型糖尿病理想的治療方案.
목적 비교감정이도소연합이갑쌍고혹/(화)아잡파당치료신진단2형당뇨병적림상료효급안전성.방법 선취84례신진단2형당뇨병환자,병사:유체질량하강,체질량지수(BMI) 23 ～ 28 kg/m2,선복용이갑쌍고지소4주,혈당공제불가,공복혈당≥10 mmol/L,찬후2h혈당(2 h BG)≥14 mmol/L적환자수궤분위삼조.A조:이갑쌍고가감정이도소;B조:아잡파당가감정이도소;C조:이갑쌍고여아잡파당가감정이도소,수방12주.결과 ①삼조치료후공복혈당、2hBG、당화혈홍단백(HbA1 c)균저우치료전,A、B량조HbA1c부분체표,C조HbA1c전부체표(P＜0.05).②C조료효우우A、B조,체표시간최단,일이도소용량최소.③A、B조BMI무증가,C조BMI유소하강(P＞0.05).④삼조저혈당발생솔균＜1 1％,무엄중저혈당사건발생,차이무통계학의의(P＞0.05).결론 감정이도소연합이갑쌍고혹/(화)아잡파당균능교호지공제혈당,대체질량영향소,저혈당발생솔저,삼약연합료효우우이약연합,총체안전、유효、방편,시신진단2형당뇨병이상적치료방안.
Objective To compare the clinical effects and safety of glargine insulin combined with metformin or/and acarbose on newly diagnosed type 2 diabetes patients.Methods Eighty-four patients with newly diagnosed type 2 diabetes,who had a history of weight loss,body mass index (BMI) 23-28 kg/m2 and poorly controlled blood glucose (fasting blood glucose ≥ 10 mmol/L,2-hour postprandial blood glucose ≥ 14 mmol/L) after use of metformin for at least a month,were randomly divided into three groups.Glargine insulin plus metformin were used in group A; Glargine insulin plus Acarbose (without mefformin) were used in group B ; Glargine insulin,acarbose and metformin were used in group C.All three groups were given a 12-week follow-up.Results ①FBG,2 h BG and HbA1c levels were lower in the patients after treatment than those before treatment in all groups (P ＜ 0.05).HbA1 c levels of patients were partly up to the standard in group A and group B,but HbA1c levels of patients were all up to the standard in group C.②The effects in group C were better than those ingroup A and group B.It had the shorest time to achieve the target and the smallest dose of insulin in group C.③BMI in group A and B did not change but decreased in group C (P ＞ 0.05).④The incidence of low blood glucose in all of the three groups was low(＜ 11％) and no significant difference occurred among the three groups (P ＞ O.05).And in all three groups no severe hypoglycemia occurred.Conclusions The method of glargine insulin combined with metformin or/and acarbose can effectively control blood glucose of the newly diagnosed type 2 diabetes patients and has little impact on body weight of the newly diagnosed type 2 diabetes patients,and moreover,the incidence of low blood glucose in the newly diagnosed type 2 diabetes patients was lower.It would be the ideal method for treating newly diagnosed type 2 diabetes patients,considering the general safety,effects and convenience.
